Lyell Immunopharma (NASDAQ:LYEL) Releases Quarterly Earnings Results

Lyell Immunopharma (NASDAQ:LYEL) released its quarterly earnings data on Wednesday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52), Zacks reports. The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%.

Lyell Immunopharma Stock Down 9.7 %

Shares of LYEL stock opened at $0.61 on Friday. Lyell Immunopharma has a 52 week low of $0.51 and a 52 week high of $3.15. The stock has a market capitalization of $177.14 million, a PE ratio of -0.77 and a beta of -0.41. The firm has a 50 day moving average of $0.63 and a two-hundred day moving average of $0.92.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Thursday.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.